荃信生物-B(02509)：QX004N进入III期临床试验及收到翰森制药的付款

Core Viewpoint - The company is developing an IL23p19 inhibitor, QX004N, for the treatment of psoriasis and Crohn's disease, and has entered into an exclusive licensing agreement with Hansoh Pharmaceutical for its development and commercialization in several regions [1] Group 1 - QX004N has recently entered Phase III clinical trials, marking it as the fourth product in the company's pipeline to reach this stage [1] - The company has received a total of RMB 58 million from Hansoh Pharmaceutical as milestone and other payments related to the Phase III trial [1]